plicity. Statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, North Carolina). 3|RESULTS 3.1 |Study population Of 808 patients screened, 511 entered the 8-week IG titration phase (Figure 1). After the IG titration phase, 464 patients were randomizedto treatment. Overall, 231 and 230 patients randomized to receive exenatide QW and placebo, respectively, met ITT criteria and were analysed for efficacy. The safety analysis set comprised 232 and 231 patients receiving exenatide QW and placebo, respectively. Study completion rates were similar between groups (exenatide QW, 91.4%; placebo, 90.0%) (Figure 1).1604 GUJA ET AL.